RYTM NASDAQ
Rhythm Pharmaceuticals, Inc.
1W: +2.2%
1M: -6.5%
3M: -13.5%
YTD: -12.2%
1Y: -16.6%
3Y: +319.0%
5Y: +738.8%
$92.18
+2.71 (+3.03%)
Weekly Expected Move ±4.1%
$82
$86
$89
$93
$97
Credit Risk of going bust: lower than 94% of companies Debt: 0.1% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.01 (down more than 99.9%), Rhythm Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $3.7M against a stock market value of $6.35B.
Distance to default 17.55 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $1.8M (short-term plus half of long-term), stock volatility 46.1%; Altman Z'' -8.13. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.01 (down more than 99.9%), Rhythm Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $3.7M against a stock market value of $6.35B.
Distance to default 17.55 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $1.8M (short-term plus half of long-term), stock volatility 46.1%; Altman Z'' -8.13. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
1 bullish
0 neutral
1 bearish
Articles (24h)
2
Hourly Sentiment (24h)
0.30
Neutral
2 bullish
0 neutral
1 bearish
Articles (7d)
3
Daily Sentiment (7 Days)
Articles (100)
Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Oppenheimer's top 50 small- and mid-cap Sell ideas
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Stock Has Consensus Target Price of $142.50 According to Brokerages
Rhythm Pharmaceuticals (RYTM) Upgraded to Buy: Here's What You Should Know
Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® (setmelanotide) for Weight Management in Adult and Pediatric Patients 4 years of Age and Older with Acquired Hypothalamic Obesity
325,470 Shares in Rhythm Pharmaceuticals, Inc. $RYTM Acquired by Bank of America Corp DE
Ultragenyx (RARE) Surges 12.6%: Is This an Indication of Further Gains?
David Meeker Sells 50,000 Shares of Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock
Rhythm Pharmaceuticals (NASDAQ:RYTM) Trading Down 5.3% on Insider Selling
California State Teachers Retirement System Grows Stock Holdings in Rhythm Pharmaceuticals, Inc. $RYTM
Bank of New York Mellon Corp Purchases Shares of 394,044 Rhythm Pharmaceuticals, Inc. $RYTM
Billionaire Stanley Druckenmiller Is Quietly Loading Up on Healthcare Stocks -- Here's What His New Positions Reveal
Eli Lilly and Novo Nordisk Can't Treat This Form of Obesity. Billionaire Stanley Druckenmiller Is Betting Rhythm Pharmaceuticals Can
Dimensional Fund Advisors LP Sells 12,867 Shares of Rhythm Pharmaceuticals, Inc. $RYTM
Rhythm Pharmaceuticals (RYTM) Q2 2026 Earnings Call Transcript
Assenagon Asset Management S.A. Invests $20.71 Million in Rhythm Pharmaceuticals, Inc. $RYTM
California State Teachers Retirement System Acquires 12,269 Shares of Rhythm Pharmaceuticals, Inc. $RYTM
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates
Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update
Here are the major earnings before the open Tuesday
Analysts Estimate Qiagen (QGEN) to Report a Decline in Earnings: What to Look Out for
Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives $138.29 Average Price Target from Brokerages
Rhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity
Is Rhythm Pharmaceuticals, Inc. (RYTM) Stock Poised for Growth After Encouraging Setmelanotide Trial Results?
Strength Seen in Acadia (ACAD): Can Its 6.8% Jump Turn into More Strength?
Rhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome (PWS) at ENDO 2026
Why Is Rhythm Pharma Stock Jumping Today?
Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026
Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome
Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome
Rhythm Pharmaceuticals Announces Seven Abstracts Accepted for Presentation at ENDO 2026
Rhythm Pharmaceuticals Announces Seven Abstracts Accepted for Presentation at ENDO 2026
My Top 3 Stocks to Buy in May
Rhythm Pharmaceuticals Analysts Boost Their Forecasts Following Upbeat Q1 Results
Rhythm (RYTM) Q1 2026 Earnings Call Transcript
Rhythm Pharmaceuticals Announces Participation in Upcoming Bank of America Global Healthcare Conference
Why Rhythm Pharmaceuticals Stock Triumphed on Tuesday
Rhythm outlines HO expansion with Japan approval anticipated before end of 2026
Full Transcript: Rhythm Pharmaceuticals Q1 2026 Earnings Call
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Tops Revenue Estimates
Earnings Scheduled For May 5, 2026
Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update
Rhythm Pharmaceuticals Q1 2026 Earnings Preview
Rhythm Pharmaceuticals Announces New Data Presentations in Acquired Hypothalamic Obesity at Pediatric Endocrine Society
Rhythm Pharmaceuticals Announces New Data Presentations in Acquired Hypothalamic Obesity at Pediatric Endocrine Society
Rhythm Pharmaceuticals Announces IMCIVREE® (Setmelanotide) Granted Marketing Authorization by European Commission for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity
Sarepta Therapeutics (SRPT) Reports Next Week: Wall Street Expects Earnings Growth
Analysts Estimate Rhythm Pharmaceuticals, Inc. (RYTM) to Report a Decline in Earnings: What to Look Out for
Is Rhythm Pharmaceuticals, Inc. (RYTM) A Good Stock To Buy Now?
SG Americas Securities LLC Lowers Stock Holdings in Rhythm Pharmaceuticals, Inc. $RYTM
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives Average Recommendation of “Moderate Buy” from Analysts
Strength Seen in Rhythm Pharmaceuticals (RYTM): Can Its 12.6% Jump Turn into More Strength?
Is This Weight Loss Drug Stock a Buy After a New Approval?
Rhythm Pharma wins EU backing to expand Imcivree label
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment
Rhythm Pharmaceuticals (NASDAQ:RYTM) Shares Gap Up – Time to Buy?
HC Wainwright Issues Negative Forecast for RYTM Earnings
PANTHERx® Rare Selected by Rhythm Pharmaceuticals Inc. as the Exclusive U.S. Specialty Pharmacy for the Expanded Indication for IMCIVREE® (setmelanotide)
Rhythm Pharma Wins FDA Approval For First-Ever Rare Weight Disorder Therapy
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity
Revolution, Ascendis, Arrowhead among RBC’s top M&A candidates in biotech
Microvast, Dragonfly Energy, Natural Gas Services And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Rhythm Pharmaceuticals Rare Obesity Drug Study Disappoints
Rhythm Pharma down after late-stage trial setback for lead asset in rare obesity disorders
Stock Market Today: S&P 500, Dow Jones Futures Tumble As US Allies Reject Trump's Call To Deploy Navy At Hormuz—Uber, Lululemon, Cisco In Focus
Rhythm Pharmaceuticals, Inc. $RYTM Shares Bought by Aquatic Capital Management LLC
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives $133.19 Average Target Price from Brokerages
Rhythm Pharmaceuticals Announces Topline Results from Phase 3 EMANATE Trial
Rhythm Pharmaceuticals Announces Topline Results from Phase 3 EMANATE Trial
Cinctive Capital Management LP Sells 35,781 Shares of Rhythm Pharmaceuticals, Inc. $RYTM
Algert Global LLC Increases Stake in Rhythm Pharmaceuticals, Inc. $RYTM
Catalyst Watch: Nvidia's GTC Conference, FOMC meeting, Okta event, and triple-witching day
DNB Asset Management AS Takes Position in Rhythm Pharmaceuticals, Inc. $RYTM
Research Analysts Set Expectations for RYTM Q1 Earnings
What is HC Wainwright’s Estimate for RYTM FY2027 Earnings?
Rhythm Pharmaceuticals Discloses 18.8% BMI Drop In Rare Obesity Patients
Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity
Rhythm anticipates $385M–$415M in 2026 non-GAAP operating expenses as HO launch preparations accelerate
Rhythm Pharmaceuticals, Inc. (RYTM) Q4 2025 Earnings Call Transcript
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Beats Revenue Estimates
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update
Here are the major earnings before the open Thursday
Rhythm Pharmaceuticals Q4 2025 Earnings Preview
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026
Rhythm Pharmaceuticals Eyes March 20 HO PDUFA, Highlights IMCIVREE Growth at Guggenheim Conf.
Rhythm Pharmaceuticals (NASDAQ:RYTM) CFO Sells $358,588.86 in Stock
Penserra Capital Management LLC Acquires Shares of 30,436 Rhythm Pharmaceuticals, Inc. $RYTM
Rhythm Pharmaceuticals Announces Participation in Upcoming Guggenheim Biotech Summit
This High-Flying Growth Stock Is Hiding in Plain Sight
EFG Asset Management North America Corp. Invests $2.05 Million in Rhythm Pharmaceuticals, Inc. $RYTM
Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Product Revenues and Upcoming Milestones
VIRGINIA RETIREMENT SYSTEMS ET Al Takes Position in Rhythm Pharmaceuticals, Inc. $RYTM
Assenagon Asset Management S.A. Sells 13,870 Shares of Rhythm Pharmaceuticals, Inc. $RYTM
Alkeon Capital Management LLC Grows Holdings in Rhythm Pharmaceuticals, Inc. $RYTM
Rhythm: PWS Signal, HO Speed Bump, And The Case For A Rare-Obesity Blockbuster
Rhythm Pharmaceuticals, Inc. (RYTM) Discusses Preliminary Phase II Data of Setmelanotide in Prader-Willi Syndrome and Next Steps Transcript
Rhythm Pharma Hits Record High On Unexpected Obesity-Tied Win
Rhythm Pharma Strikes Chord As Early PWS Trial Results Show Promise
Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome